Build the next generation of therapies together
Agave Biomedical Industries partners with biopharma companies, academic medical centers, research institutions, and investors to advance drug discovery, genomics, diagnostics, and gene therapy. We are actively seeking collaborations that turn scientific insight into clinical impact.
Ways to partner with us
Collaborative research
Joint discovery programs that combine our disease biology expertise with partner compounds, targets, or patient data. We share risk and align incentives from milestone to market.
Licensing & IP
Out-license early-stage assets, biomarker panels, or platform technologies in oncology, neurodegeneration, and gene therapy. We structure deals that preserve upside for both parties.
Investment & venture
We welcome strategic investment to advance our pipeline. Partner with us at the discovery stage and benefit from program-level milestones and transparent progress reporting.
CRO & advisory services
Access our computational biology, genomics analysis, and drug-compatibility modeling capabilities on a fee-for-service or advisory basis for your own programs.
Capabilities partners can tap into
Our interdisciplinary team combines deep biology with modern data science. We can plug into a partner's existing pipeline or lead early discovery from target to preclinical candidate.
- Target identification & validation
- Computational drug-drug interaction modeling
- Whole-genome and transcriptomic analysis
- Biomarker discovery & diagnostics development
- Preclinical strategy & translational planning
- Natural product & bioactive compound screening
Diseases we are working to change
Our current pipeline prioritizes diseases with high unmet need and strong biological rationale for gene therapy, precision medicine, and novel drug combinations.
Oncology
Solid tumors and hematologic malignancies with a focus on combination therapy and biomarker-guided treatment.
Neurodegeneration
Parkinson's, Alzheimer's, and related dementias, exploring disease-modifying mechanisms and gene therapy delivery.
Rare disease
Monogenic conditions where gene therapy, natural product chemistry, or targeted small molecules can transform outcomes.
Start the conversation
Tell us about your program, target, or investment thesis. We'll respond within two business days to explore how we can work together.